Abstract

BackgroundA high percentage of patients with thin melanoma (TM), defined as lesions with Breslow thickness ≤1 mm, presents excellent long-term survival, however, some patients develop metastases. Existing prognostic factors cannot reliably differentiate TM patients at risk for metastases.ObjectiveWe aimed at characterizing the clinical-pathologic and mutation profile of metastatic and not-metastatic TM in order to distinguish lesions at risk of metastases.MethodsClinical-pathologic characteristics were recorded for the TM cases analyzed. We used a Next Generation Sequencing (NGS) multi-gene panel to characterize TM for multiple somatic mutations.ResultsA statistically significant association emerged between the presence of metastases and Breslow thickness ≥0.6 mm (p=0.003). None of TM with lymph-node involvement had Breslow thickness <0.6 mm. Somatic mutations were identified in 19 of 21 TM analyzed (90.5%). No mutations were observed in two not-metastatic cases with the lowest Breslow thickness (≤0.4 mm), whereas mutations in more than one gene were detected in one metastatic case with the highest Breslow thickness (1.00 mm).ConclusionOur study indicates Breslow thickness ≥0.6 mm as a valid prognostic factor to distinguish TM at risk for metastases.

Highlights

  • From a clinical and molecular standpoint, melanoma is a complex, heterogeneous and unpredictable disease

  • Clinical-pathologic characteristics were recorded for the thin melanoma (TM) cases analyzed

  • A statistically significant association emerged between the presence of metastases and Breslow thickness ≥0.6 mm (p=0.003)

Read more

Summary

Introduction

From a clinical and molecular standpoint, melanoma is a complex, heterogeneous and unpredictable disease. The incidence of malignant melanoma (MM) has drastically increased in the past decades [1]. 70% of new cases of MM are thin melanomas (TM), which are lesions ≤1.00 mm in Breslow thickness, and TM diagnosis are increasing around the world [2]. Thin tumors have a 10-year survival rate of 85-90% [3]. The high percentage of TM without recurrences is in contrast with a group that could develop recurrences and regional or distant metastases [4,5,6,7]. A high percentage of patients with thin melanoma (TM), defined as lesions with Breslow thickness ≤1 mm, presents excellent long-term survival, some patients develop metastases. Existing prognostic factors cannot reliably differentiate TM patients at risk for metastases

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call